Icariin Ameliorates Neuropathological Changes, TGF-β1 Accumulation and Behavioral Deficits in a Mouse Model of Cerebral Amyloidosis

Zhang, Zhi Yuan; Li, Chaoyun; Zug, Caroline; Schluesener, Hermann J.

doi:10.1371/journal.pone.0104616

Cited by 24 publications

(17 citation statements)

References 57 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In research of Li F et al, ICA has instigated the improvement of memory function, as well as reducing Aβ and APP levels in the brain [3]. A similar conclusion was made by Zhang ZY et al, assessing the effect of Icariin onan animal model of cerebral amyloidosis for AD in transgenic APP/PS1 mouse [6]. In the study by Zhang, L. et al, in addition, there was a reduction in β-amyloid burden, and a decrease in APP, and beta-site amyloid precursor protein cleaving enzyme 1 (BACE-1) expression was observed in the transgenic mouse APP model of AD [7].…”

Section: Methodsmentioning

confidence: 62%

Icariin as a new potential drug in Alzheimer disease treatment – a review

Piędel¹,

Petit²,

Rejdak³

2019

J Pre Clin Clin Res.

View full text Add to dashboard Cite

Introduction. Alzheimer disease (AD) is one of the best-known diseases. It is neurodegenerative disease characterized by gradual memory loss and dysfunction of behaviour. The pathogenesis of this disease is unclear. Icariin (ICA) is a flavonoid found in a Chinese medicinal herb. It is recognised for a wide range of biological and medical activities: anti-tumour and anti-inflammatory, and also has an impact on the nervous system: stimulates neuroproliferation and prevents neuron's apoptosis. ICA may have a potential role in AD disease treatment. Objective. The purpose of this article is to review current knowledge about mechanisms and use of ICA in AD treatment. State of knowledge. AD does not present established pathomechanism, about which there are some hypotheses. Each hypothesis mentioned and checked in this review, with result that ICA may have a potential role. One well-known hypothesis is that about amylolytic which is associated with amyloid precursor protein (APP) gene mutation, which leads to amyloid beta (Aβ) protein accumulation and to occurenc of the disease. In this hypothesis, ICA may inhibit Aβ protein aggregation or alter APP expression. ICA may stifle neuronal apoptosis and promote neurogenesis and neuromodulation. According to other hypotheses, ICA could also impact on iron overload in the brain, harmful for neurons hyperhomocysteinaemia, disorder of the intracellular calcium management. Modification of theTau protein structure is another one theory of ICA action. Flavonoid from China may also have an influence on axonal transport. Conclusions. According to the literature there is no single mechanism of ICA action in slowing down AD progress. A wide range of therapeutic points is demonstrated by the broad effect of this substance. Further research is mandatory.

show abstract

Section: Methodsmentioning

confidence: 62%

Icariin as a new potential drug in Alzheimer disease treatment – a review

Piędel¹,

Petit²,

Rejdak³

2019

J Pre Clin Clin Res.

View full text Add to dashboard Cite

show abstract

“…7E ]. Our previous results [16] showed a significant reduction in plaque numbers in the cortex of icariin- and hesperidin-treated mice [experiment Ⅱ, control Ⅱ=149.0 (128.5–197.8), icariin=100.5 (61.8–130.3), P ≤0.05, Fig. 7C ; experiment Ⅲ, control Ⅲ=157.0 (147.0–169.3), hesperidin=126.0 (103.0–142.0), P ≤0.05, Fig.…”

Section: Resultsmentioning

confidence: 99%

Computer-aided identification of protein targets of four polyphenols in Alzheimer's disease (AD) and validation in a mouse AD model

Meng

Zhang

et al. 2019

J Biomed Res

View full text Add to dashboard Cite

Natural polyphenols are a large class of phytochemicals with neuroprotective effects. Four polyphenolic compounds: hesperidin, icariin, dihydromyricetin and baicalin were selected to evaluate their effects on Alzheimer's disease (AD). We analyzed by an inverse docking procedure (INVDOCK) the potential protein targets of these polyphenols within the KEGG AD pathway. Consequently, their therapeutic effects were evaluated and compared in a transgenic APP/PS1 mouse model of AD. These polyphenols were docked to several targets, including APP, BACE, PSEN, IDE, CASP, calpain and TNF-α, suggesting potential in vivo activities. Five month old transgenic mice were treated with these polyphenols. Icariin and hesperidin restored behavioral deficits and ameliorated Aβ deposits in both the cortex and hippocampus while baicalin and dihydromyricetin showed no substantial effects. Our findings suggest that hesperidin and icariin could be considered potential therapeutic candidates of human AD.

show abstract

“…Icariin, a main constituent of Epimedii Herba and a well-known tonic crude drug, has been found to have a remarkable effect on AD in the past 10 years. Researchers found that icariin could reduce the Aβ burden and amyloid plaque deposition in the hippocampus of AD transgenic mice, 36,50,51 and preserve the expression of synaptic functional proteins and improve synaptic function. 42 Ginsenoside could attenuate pathological tau phosphorylation 37 and ameliorate hippocampal Aβ deposition in AD mice.…”

Section: Discussionmentioning

confidence: 99%

Effect of Herbal Medicinal Compounds on Alzheimer’s Disease Pathology in APP/PS1 Transgenic Mouse Model

Wang

et al. 2020

Natural Product Communications

View full text Add to dashboard Cite

The pathogenesis of Alzheimer’s disease (AD) is complex as various mechanisms interact with each other and, therefore, intervention from a single target is often ineffective. Many studies have shown that herbal medicines, such as curcumin, fisetin, icariin, and ginsenosides, have significant intervention effects on AD with different treatment mechanisms. Therefore, we have designed this study to know whether the combination of these herbal medicines can have an intervention effect on AD through multiple targets. Amyloid precursor protein/presenilin 1(APP/PS1) double transgenic AD mice were used to study the protective effects of a combination of curcumin, piperine, icariin, and ginsenosides, as well as a combination of fisetin, piperine, icariin, and ginsenosides, which were separately mixed into the feed. These herbal medicinal compounds (HMCs) lowered the serum lipid levels, reduced the Aβ oligomers, decreased the pS404-tau protein, as well as neurofibrillary tangles, and restored the reduction of synaptic protein levels and neuronal death of AD mice without causing toxicity to liver and kidneys. In this study, we found that HMCs have significant intervention against AD through multiple targets, providing a novel therapeutic idea for the prevention of AD.

show abstract

Icariin Ameliorates Neuropathological Changes, TGF-β1 Accumulation and Behavioral Deficits in a Mouse Model of Cerebral Amyloidosis

Cited by 24 publications

References 57 publications

Icariin as a new potential drug in Alzheimer disease treatment – a review

Icariin as a new potential drug in Alzheimer disease treatment – a review

Computer-aided identification of protein targets of four polyphenols in Alzheimer's disease (AD) and validation in a mouse AD model

Effect of Herbal Medicinal Compounds on Alzheimer’s Disease Pathology in APP/PS1 Transgenic Mouse Model

Contact Info

Product

Resources

About